Concert Pharmaceuticals Inc. (CNCE) Has Risen To A New High After New CFO Named

Concert Pharmaceuticals Inc. (CNCE) announced Monday that Marc Becker has been appointed as its new Chief Financial Officer, effective January 4, 2018.

Concert Pharmaceuticals gapped up Monday and has continued to climb in early trade. Shares are now up 2.35 at $29.90 on above average volume. The stock has been on an upward trend for over a month and has set a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT